Zacks Research Has Negative View of OPKO Health Q3 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Stock analysts at Zacks Research dropped their Q3 2026 EPS estimates for shares of OPKO Health in a research note issued on Thursday, March 19th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The business’s revenue was down 19.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.01 earnings per share.

A number of other research analysts have also weighed in on OPK. Barrington Research decreased their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, OPKO Health presently has an average rating of “Hold” and an average price target of $2.03.

OPKO Health Stock Down 1.7%

Shares of OPK opened at $1.13 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.52 and a current ratio of 3.97. OPKO Health has a one year low of $1.10 and a one year high of $1.81. The stock has a market capitalization of $857.75 million, a price-to-earnings ratio of -3.77 and a beta of 1.50. The stock has a 50 day moving average price of $1.23 and a 200 day moving average price of $1.33.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors and hedge funds have recently made changes to their positions in OPK. World Investment Advisors lifted its holdings in shares of OPKO Health by 63.8% in the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 25,902 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in OPKO Health by 1,056.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 35,841 shares during the last quarter. Virtu Financial LLC purchased a new stake in OPKO Health in the fourth quarter valued at approximately $145,000. EP Wealth Advisors LLC acquired a new position in OPKO Health during the fourth quarter worth $37,000. Finally, XTX Topco Ltd acquired a new position in OPKO Health during the fourth quarter worth $432,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.